Portfolio of Current Investments
 |
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer. The company also markets the industry's most comprehensive kinase profiling service through its KinomeScan Division. KinomeScan is a proprietary technology designed to screen small molecule libraries against large numbers of human kinases for the purpose of rapidly advancing drug candidates with best-in-class potency and selectivity. Ambit has multiple drug candidates in pre-clinical and clinical development, including AC220, a selective class III receptor tyrosine kinase inhibitor currently in Phase I for treatment of acute myeloid leukemia. The company has partnerships with Roche, Bristol-Myers Squibb, GlaxoSmithKline, Cephalon, and other leading organizations. For more information, please visit www.ambitbio.com. |
 |
Applied Genetic Technologies Corporation is focused on developing gene therapy products derived from adeno-associated virus (AAV) for the treatment of inherited and acquired diseases. |
 |
Critical Therapeutics, Inc. is a publicly traded biopharmaceutical company (NASDAQ: CRTX) focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases. The company aims to become a leading biopharmaceutical company focused on developing therapeutics directed at the inflammatory response associated with asthma and critical care diseases. News |
 |
Elusys Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of targeted anti-infective therapeutics using proprietary Heteropolymer (HP) Antibodies for the treatment of infectious disease. The company's Heteropolymer Antibody Technology has demonstrated a unique ability to clear and destroy pathogens and provides a platform to develop a deep pipeline of novel drug candidates targeted against bacterial, viral and fungal infections. News |
 |
Inotek Pharmaceuticals is a multinational biopharmaceutical firm focused on discovery, research and the development of novel pharmaceutical technologies with potential applications in critical care, surgery, trauma, transplantation, and auto-immune diseases. News |
 |
Iomai Corp. has pioneered the successful delivery of vaccines and immunostimulants to the skin. The company's proprietary technology, known as transcutaneous immunization or TCI, is founded on the biological insight that the skin is a highly attractive immune environment that can be safely manipulated for purposes of vaccination. Iomai is the exclusive licensee of transcutaneous immunization technology from the U.S. government and has one hundred patent applications pending worldwide. News |
 |
Kémia, Inc. is a biopharmaceutical company that discovers and develops novel small molecule therapeutics, with a focus on validated disease targets not yet addressed by safe and effective non-injectable drugs. News |
 |
Metastatix, Inc. is a pharmaceutical company focused on the development of effective small-molecule drugs that are easy to take and have the fewest possible side effects. The company has used rational drug design to create a portfolio of potent and structurally novel antagonists to the CXCR4 chemokine receptor, a critical mediator of cellular and chemical trafficking. News |
 |
Micromet implements novel concepts in antibody therapy, creating new options for the treatment of cancer, inflammation and autoimmune diseases. Unique to Micromet is BiTE™ (Bispecific T cell engagers), a novel class of antibody derivatives, which stand out in terms of therapeutic potency and economy of production. Micromet's drug candidate portfolio includes a human antibody and various compounds from the BiTE™ family. News |
 |
Rib-X Pharmaceuticals, Inc. is a small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The company's underlying drug discovery engine is based on its proprietary high-resolution crystal structure of the 50S subunit of the ribosome, which performs an essential role in the fundamental process of protein synthesis. News |
 |
Sequoia Pharmaceuticals, Inc. is engaged in the discovery and development of novel antiviral therapeutics, with a focus on developing new treatments for drug-resistant infectious diseases such as HIV/AIDS and HCV-induced hepatitis. Sequoia Pharmaceuticals is located in Gaithersburg, Md. News |
 |
Tercica, Inc., is a publicly traded biopharmaceutical company (NASDAQ: TRCA) focused on the development and commercialization of new therapeutics for endocrine system disorders, including short stature and diabetes. The company's lead compound in development is recombinant human Insulin-Like Growth Factor-I (rhIGF-I), a hormone with a broad range of activity central to human growth and metabolism. News |
 |
VaxInnate is exploiting a growing knowledge base about the field of innate immunity, which suggests that elements of the innate immune system initiate and control the adaptive immune response. VaxInnate hopes to produce a proprietary vaccine that triggers both the innate and adaptive immune response in a controlled fashion, with the potential for extremely high vaccine potency and specificity and a reduction or elimination of excessive inflammation problems. News |
 |
VLST Corporation is a privately held biotechnology company focused on the discovery and development of therapeutics for the treatment of inflammatory and autoimmune diseases. Disease areas in which the company’s technology may have utility include multiple sclerosis, lupus, cardiovascular disease, diabetes and obesity. News |
 |
Xencor, Inc. is focused on the field of antibody Fc engineering to significantly improve antibody potency, using its proprietary Protein Design Automation® technology platform. The company is internally advancing both XPro™ protein therapeutic candidates and XmAb™ antibody drug candidates optimized for activity against biologically validated targets. News |